Myriad Genetics, Inc. (MYGN)
Myriad Genetics is genetic testing and precision medicine company. Co. provides insights that help people take control of their health and enable healthcare providers to detect, treat, and prevent disease. Co. discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical personnel. Co.'s molecular diagnostic tests are designed to analyze genes and their expression levels to assess an individual's risk for developing disease, determine a patient's likelihood of responding to a particular drug, or assess a patient's risk of disease progression.
MYGN SEC Filing Email Alerts Service
| Company Name: |
Myriad Genetics, Inc. |
| Stock buyback: |
MYGN buyback |
| Website: |
www.myriad.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding MYGN: |
51 |
| Total Market Value Held by ETFs: |
$428.74M |
| Total Market Capitalization: |
$1.70B |
| % of Market Cap. Held by ETFs: |
25.22% |
|
|
April 18, 2024 • 6:32 PM Eastern
Hold (2.36 out of 4)
100th percentile
|
|
Free MYGN Email Alerts:
